MOROXYDINE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C6H13N5O
Molecular Weight	171.2003
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NC(=N)NC(=N)N1CCOCC1

InChI

InChIKey=KJHOZAZQWVKILO-UHFFFAOYSA-N

InChI=1S/C6H13N5O/c7-5(8)10-6(9)11-1-3-12-4-2-11/h1-4H2,(H5,7,8,9,10)

HIDE SMILES / InChI

Molecular Formula	C6H13N5O
Molecular Weight	171.2003
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9868507 | https://www.ncbi.nlm.nih.gov/pubmed/26428870

Moroxydine is an antiviral drug discovered in the 1950’s which was shown to be active against DNA and RNA viruses. Moroxydine analogues are potent anti-hepatitis C virus (HCV) agents.

Originator

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
Viral infection 4 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9868507	Primary		Approved 8583	VIRULEX FORTE Approved Use Unknown

Doses

Dose	Population	Adverse events
0.04 g/kg 1 times / day steady, Studied dose Dose: 0.04 g/kg, 1 times / day Route: steady Dose: 0.04 g/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6963328/	unhealthy Health Status: unhealthy Sex: unknown Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/6963328/	Disc. AE: Diarrhea, Itching... AEs leading to discontinuation/dose reduction: Diarrhea (2 patients) Itching (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/6963328/

AEs

AE	Significance	Dose	Population
Itching	1 patient Disc. AE	0.04 g/kg 1 times / day steady, Studied dose Dose: 0.04 g/kg, 1 times / day Route: steady Dose: 0.04 g/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6963328/	unhealthy Health Status: unhealthy Sex: unknown Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/6963328/
Diarrhea	2 patients Disc. AE	0.04 g/kg 1 times / day steady, Studied dose Dose: 0.04 g/kg, 1 times / day Route: steady Dose: 0.04 g/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6963328/	unhealthy Health Status: unhealthy Sex: unknown Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/6963328/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252	inhibitor 2438	inhibitor 2507

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2C19 2057 CYP1A2 2153	P-gp 2052

Drug as perpetrator

Target	Modality	Activity
CYP1A2 2333	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzU2IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE0OTA0MzQifX0=	no [IC50 >10 uM]
CYP2C19 2141	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNjIyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE0OTA0MzQifX0=	no [IC50 >10 uM]
CYP2C9 2497	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzk3IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE0OTA0MzQifX0=	no [IC50 >10 uM]
CYP2D6 2546	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyODkiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMMTQ5MDQzNCJ9fQ==	no [IC50 >10 uM]
CYP3A4 2633	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMMTQ5MDQzNCJ9fQ==	no [IC50 >10 uM]

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 2052	substrate 4014 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/71655#section=Biological-Test-Results Page: 64 \| 67	no

PubMed

Title	Date	PubMed
[The influense of guanidine derivatives on free radical oxidation intensity and aconitase activity at development of brain ischemia-reperfusion at rats].	2009-12-19	20017395
Effect of N-[Imino(4-morpholyl)methyl]guanidine on the oxidative status in rats with toxic hepatitis.	2009-10	20396755
Study of molecularly imprinted solid-phase extraction of diphenylguanidine and its structural analogs.	2009-04-20	19345756
Trisodium bis-{1-[iminio-(morpholino)meth-yl]guanidinium} bis-[hexa-hydrogen-hexa-molybdoaluminate(III)] chloride icosa-hydrate.	2008-07-26	21203050

Patents

Sample Use Guides

In Vivo Use Guide

Daily dose ranges from 25 to 5600 mg.

Route of Administration: Other

In Vitro Use Guide

6.3 μg/mL Moroxydine suppresses apoptosis in grass carp reovirus (GCRV)-infected Ctenopharyngodon idella kidney (CIK) cells.

Substance Class	Chemical Created by `admin` on `Wed Apr 02 08:46:57 GMT 2025` Edited by `admin` on `Wed Apr 02 08:46:57 GMT 2025`
Record UNII	O611591WAH
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

MOROXYDINE

Official Name

English

SKF 8898-A

Preferred Name

English

SKF-8898A

Code

English

SKF-8898-A

Code

English

MOROXYDINE [MI]

Common Name

English

moroxydine [INN]

Common Name

English

N-CARBAMIMIDOYLMORPHOLINE-4-CARBOXIMIDAMIDE

Systematic Name

English

N-(AMINOIMINOMETHYL)-4-MORPHOLINECARBOXIMIDAMIDE

Systematic Name

English

ABOB

Common Name

English

Moroxydine [WHO-DD]

Common Name

English

4-MORPHOLINECARBOXIMIDOYLGUANIDINE

Systematic Name

English

MOROXYDINE [MART.]

Common Name

English

Classification Tree Code System Code

WHO-ATC

J05AX01